These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28431778)

  • 1. Olmesartan.
    Al-Majed AA; Bakheit AHH; Abdel Aziz HA; Al-Jallal AAM
    Profiles Drug Subst Excip Relat Methodol; 2017; 42():241-286. PubMed ID: 28431778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan.
    Bakheit AH; Abd-Elgalil AA; Mustafa B; Haque A; Wani TA
    Profiles Drug Subst Excip Relat Methodol; 2015; 40():371-429. PubMed ID: 26051689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propranolol.
    Al-Majed AA; Bakheit AHH; Abdel Aziz HA; Alajmi FM; AlRabiah H
    Profiles Drug Subst Excip Relat Methodol; 2017; 42():287-338. PubMed ID: 28431779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan: Comprehensive Profile.
    Al-Majed AR; Assiri E; Khalil NY; Abdel-Aziz HA
    Profiles Drug Subst Excip Relat Methodol; 2015; 40():159-94. PubMed ID: 26051686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF; Franks AM
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
    Chrysant SG; Dimas B; Shiraz M
    J Hum Hypertens; 2007 Sep; 21(9):699-708. PubMed ID: 17554345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirtazapine.
    Al-Majed A; Bakheit AH; Alharbi RM; Abdel Aziz HA
    Profiles Drug Subst Excip Relat Methodol; 2018; 43():209-254. PubMed ID: 29678261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
    Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
    Ishii M
    Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.
    Matsumoto S; Shimodozono M; Miyata R; Kawahira K
    Hypertens Res; 2009 Nov; 32(11):1015-21. PubMed ID: 19745828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus].
    Lancellotti P
    Rev Med Liege; 2007 Mar; 62(3):175-9. PubMed ID: 17511387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG; Chavanu KJ; Xu J
    Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
    Rump LC; Sellin L
    Expert Opin Pharmacother; 2010 Sep; 11(13):2231-42. PubMed ID: 20707758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olmesartan medoxomil: recent clinical and experimental acquisitions.
    Destro M; Preti P; D'Ospina A; Christian Achiri NN; Ricci AR; Cagnoni F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1149-57. PubMed ID: 19689219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
    Zannad F; Fay R
    Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.